TMPRSS2-ETS gene fusion in prostate cancer;Die TMPRSS2-ETS-genfusion beim prostatakarzinom

Urologe - Ausgabe A

Volumn 46, Issue 7, 2007, Pages 754-760

  Perner, S ^a,b   Schmidt, F H ^a   Hofer, M D ^a   Kuefer, R ^b   Rubin, M ^a,c,d  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY HOSPITAL ULM   (Germany)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

ERG; ETS; Gene fusion; Prostate cancer; TMPRSS2

Indexed keywords

IMATINIB; PROSTATE SPECIFIC ANTIGEN; TRANSCRIPTION FACTOR ER81; TRANSCRIPTION FACTOR ETS;

ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER MORTALITY; CANCER SURGERY; CHROMOSOME 21; CHRONIC MYELOID LEUKEMIA; DIAGNOSTIC TEST; DISEASE COURSE; EWING SARCOMA; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE FUSION; HUMAN; OUTCOME ASSESSMENT; PHILADELPHIA 1 CHROMOSOME; PROSTATE CANCER; PROSTATE HYPERTROPHY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TMPRSS2 ETS GENE; TRANSURETHRAL RESECTION;

GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; NEOPLASM PROTEINS; ONCOGENE FUSION; PREVALENCE; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-ETS; SERINE ENDOPEPTIDASES; TUMOR MARKERS, BIOLOGICAL;

EID: 34447269708     PISSN: 03402592     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00120-007-1347-0     Document Type: Article

References (24)

1. Jemal A, Siegel R, Ward E et al. (2006) Cancer statistics, 2006. CA Cancer J Clin 56: 106-130
2. Tomlins SA, Rhodes DR, Perner S et al. (2005) Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310: 644-648
3. Rubin MA, Chinnaiyan AM (2006) Bioinformatics approach leads to the discovery of the TMPRSS2: ETS gene fusion in prostate cancer. Lab Invest 86(11): 1099-1102
4. Tomlins SA, Mehra R, Rhodes DR et al. (2006) TMPRSS2: ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res 66: 3396-3400
5. Iljin K, Wolf M, Edgren H et al. (2006) TMPRSS2 Fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming. Cancer Res 66: 10242-10246
6. Mehra R, Tomlins SA, Shen R et al. (2007) Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Mod Pathol (in press)
7. Cerveira N, Ribeiro FR, Peixoto A et al. (2006) TMPRSS2-ERG gene fusion causing ERG overexpression precedes chromosome copy number changes in prostate carcinomas and paired HGPIN lesions. Neoplasia 8: 826-832
8. Clark J, Edwards S, Feber A et al. (2003) Genome-wide screening for complete genetic loss in prostate cancer by comparative hybridization onto cDNA microarrays. Oncogene 22: 1247-1252
9. Nam RK, Sugar L, Wang Z et al. (2007) Expression of TMPRSS2 ERG gene fusion in prostate cancer cells is an important prognostic factor for cancer progression. Cancer Biol Ther 6
10. Perner S, Demichelis F, Beroukhim R et al. (2006) TMPRSS2: ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res 66: 8337-8341
11. Perner S, Mosquera J-M, Demichelis F et al. (2007) TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am J Surg Pathol (in press)
12. Soller MJ, Isaksson M, Elfving P et al. (2006) Confirmation of the high frequency of the TMPRSS2/ERG fusion gene in prostate cancer. Genes Chromosomes Cancer 45: 154-163
13. Wang J, Cai Y, Ren C, Ittmann M (2006) Expression of Variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. Cancer Res 66: 8347-8351
14. Yoshimoto M, Joshua AM, Chilton-Macneill S et al. (2006) Three-Color FISH Analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement. Neoplasia 8: 465-469
15. Demichelis F, Fall K, Perner S et al. (2007) TMPRSS2: ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene (in press)
16. Rajput AB, Miller MA, De Luca A et al. (2007) Frequency of the TMPRSS2: ERG gene fusion is increased in moderate to poorly differentiated prostate cancers. J Clin Pathol (in press)
17. Petrovics G, Liu A, Shaheduzzaman S et al. (2005) Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome. Oncogene 24: 3847-3852
18. Mosquera J-M, Perner S, Demichelis F et al. (2007) Morphological features of TMPRSS2-ERG gene fusion prostate cancer. J Pathol (in press)
19. Tada T, Ohkubo I, Niwa M et al. (1991) Immunohistochemical localization of Zn-alpha 2-glycoprotein in normal human tissues. J Histochem Cytochem 39: 1221-1226
20. Clark J, Merson S, Jhavar S et al. (2006) Diversity of TMPRSS2-ERG fusion transcripts in the human prostate. Oncogene 2006
21. Hermans KG, Marion R van, Dekken H van et al. (2006) TMPRSS2: ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer. Cancer Res 66: 10658-10663
22. Liu W, Chang B, Sauvageot J et al. (2006) Comprehensive assessment of DNA copy number alterations in human prostate cancers using Affymetrix 100 K SNP mapping array. Genes Chromosomes Cancer 45: 1018-1032
23. Hessels D, Klein Gunnewiek JM, Oort I van et al. (2003) DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 44: 8-16
24. Laxman B, Tomlins SA, Mehra R et al. (2006) Noninvasive detection of TMPRSS2: ERG fusion transcripts in the urine of men with prostate cancer. Neoplasia 8: 885-888